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Abstract
Background: This study explored the feasibility of using an Internet survey of people with
fibromyalgia (FM), with a view to providing information on demographics, sources of information,
symptoms, functionality, perceived aggravating factors, perceived triggering events, health care
utilization, management strategies, and medication use.
Methods: A survey questionnaire was developed by the National Fibromyalgia Association (NFA)
in conjunction with a task force of "experts in the field". The questionnaire underwent several
rounds of testing to improve its face validity, content validity, clarity and readability before it was
mounted on the internet. The questionnaire consisted of 121 items and is available online at the
website of the National Fibromyalgia Association.
Results: The questionnaire was completed by 2,569 people. Most were from the United States,
with at least one respondent from each of the 50 states. Respondents were predominantly middle-
aged Caucasian females, most of whom had FM symptoms for ≥ 4 years. The most common
problems were morning stiffness, fatigue, nonrestorative sleep, pain, concentration, and memory.
Aggravating factors included: emotional distress, weather changes, insomnia, and strenuous activity.
Respondents rated the most effective management modalities as rest, heat, pain medications,
antidepressants, and hypnotics. The most commonly used medications were: acetaminophen,
ibuprofen, naproxen, cyclobenzaprine, amitriptyline, and aspirin. The medications perceived to be
the most effective were: hydrocodone preparations, aprazolam, oxycodone preparations,
zolpidem, cyclobenzaprine, and clonazepam.
Conclusion: This survey provides a snap-shot of FM at the end of 2005, as reported by a self-
selected population of people. This descriptive data has a heuristic function, in that it identifies
several issues for further research, such as the prescribing habits of FM health care providers, the
role of emotional precipitants, the impact of obesity, the significance of low back pain and the
nature of FM related stiffness.
Background
Over the past 20 years fibromyalgia (FM) has emerged as
a leading cause of office visits to rheumatologists, both in
its primary form and as an accompaniment of other rheu-
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matic disorders. Epidemiological studies report a FM prev-
alence of between 2 and 7% in most nations [1-12], with
a female to male ratio of approximately 9:1. It is increas-
ingly evident that FM represents a significant challenge in
view of its high prevalence, frequent comorbidities, and
frustration with current treatment modalities.
Patient self-report is increasingly used to assess the impact
of rheumatic diseases and gain insight into their impact
and to formulate new questions for investigation [13-16].
Study groups such as OMERACT (Outcome Measures in
Rheumatology) use self-reported information as a prelim-
inary step in the development of Delphi-based question-
naires with the eventual aim of defining optimal outcome
measures for clinical trials [17].
The major aims of the current study were to conduct a
large internet-based national survey of people with FM to
determine: (1) demographics and sources of information
about FM, (2) symptoms and functionality, (3) perceived
aggravating factors, (4) perceived triggering events, (5)
diagnosis and health care utilization, (6) management
strategies, and (7) medication use.
Methods
Questionnaire development
This questionnaire was developed in conjunction with
The National Fibromyalgia Association (NFA) and a
multidisciplinary Task Force of FM experts. The NFA is a
nonprofit organization whose mission is to develop and
execute programs dedicated to improving the quality of
life for people with FM by increasing the awareness of the
public, media, government, and medical community. The
first draft of the questionnaire was completed in 2004
with a focus group of 12 FM volunteers providing feed-
back.
In order to establish content validity of the Questionnaire
the following steps were taken:
• The questionnaire was administered to 42 people (ages
24–74) diagnosed with FM who attended a symposium
on FM that was held at California State University, Fuller-
ton. Based on the resulting feedback, the questionnaire
was modified to improve its content, clarity, readability,
and overall quality.
￿ The revised questionnaire was further tested on the a
focus group of 21 people with FM (age range 36–60) who
had volunteered to participate in NFA surveys via e-mail.
Based on feedback from this focus group, the Question-
naire was further adapted to further improve its content,
clarity, readability, and quality.
￿ A 2-day workshop of the Task Force met in October
2005 to finalize the Questionnaire content and format.
￿ A study was conducted to determine whether the final-
ized Questionnaire had appropriate stability over a 1–2
week period. Intraclass correlation coefficients (ICCs)
were calculated to index test-retest reliability. The majority
of the single ICC values fell within the acceptable range of
values from 0.82 to 1.00 with few exceptions. Most items
with lower ICCs required participants to recall specific
dates or to estimate things which occurred within a speci-
fied time frame (i.e., recall issues). Others items with
lower ICCs related to symptoms and states (i.e., clinical
features that typically fluctuate in intensity and fre-
quency).
The reading level of the Questionnaire, except for section
# 6 (medications), was estimated by using the "readability
statistics" tool that is available in Microsoft Word. This
analysis showed a Flesch Reading Ease score of 60.8 and a
Flesch-Kincaid Grade Level of 7.0. The grade level esti-
mates range from grade 5 through college; grade 7 is fairly
low; indicating the Questionnaire was quite suitable for
use by lay people.
The final Questionnaire consisted of 121 items [18] and
consisted of 5 sections:
(1) Background Information (questions 1–25), (2) Symp-
toms (questions 26–51), (3) Physical Ability Impact
(questions 52–63), (4) Employment Impact (questions
64–87), and (5) nature and effectiveness of interventions
(questions 88–121). A decision was made to post the sur-
vey on the Internet for whatever period was required to
obtain a representative sample of approximately 3,000
responses.
Results
The questionnaire was posted on the NFA's website on
October 12, 2005. The survey was completed in a satisfac-
tory manner by 2,569 people over the course of 3 days.
The vast majority of responses were from the United
States. There was at least 1 responder from each of the 50
States in the United States. In most States approximately
0.05% of the estimated female FM population responded
to the survey -based on a conservative estimate FM preva-
lence of 3.5% in women and the 2002 National Census
figures [19]. In addition, there were 46 responses from 12
other countries (Canada, United Kingdom, Ireland, Aus-
tralia, New Zealand, Mexico, Germany, Holland, Ber-
muda, France, Israel, and Hungary).
Demographics and the sources of information about FM
The demographics of the population responding to the
survey are shown in Table 1. The responders were pre-BMC Musculoskeletal Disorders 2007, 8:27 http://www.biomedcentral.com/1471-2474/8/27
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dominantly middle-aged Caucasian females, 75% of
whom had experienced FM symptoms for more than 4
years. Only 3.2% of the responders were male. The age
distribution was slightly skewed towards older individu-
als (mean = 47.3 ± 10.68, range 17–77.5) which is consist-
ent with published research on FM. They tended to be
moderately overweight and reported having gained
approximately 50 pounds since they were aged 18. Sev-
enty percent had a BMI > 25 and 43% had a BMI > 30;
comparable BMI figures for white females taken from
National Health Interview Survey of 2004 are 47% and
21% respectively [19]. Just over 50% of the responders
had a household income of between $20,000 and
$80,000.
Respondents obtained information about FM from
diverse sources, including professional and consumer
organizations: Health care professionals providing FM
information were: family physicians (45.8%), rheumatol-
ogist (43.6%), internists (23.1%), massage therapists
(20.3%), chiropractors (20.2%), physical therapists
(14.4%), mental health professionals (psychiatrist/psy-
chologist/social workers) (13.1%), pharmacists (7.8%),
nurse practitioners/physician assistants (7.6%), nurses
(5.3%), nutritionist/dietitians (4.4%), and gynecologists
(2.9%). In addition to health care professionals, respond-
ents received information from a number of other sources
including: NFA (sponsors of the survey,70%), general
media (41.6%), Arthritis Foundation (35.2%), Internet
message boards (23.4%), Internet chat rooms (12.5%),
local support groups (12%), and informal sources (e.g.,
friends,32.6%), health food store,13.6%, family mem-
ber,10.7%). These percentages do not summate to 100%
as more than one source could be acknowledged.
Table 1: Demographic profile of responders
Demographic Feature Frequency
Age [years] 47.3 ± 10.68
Female 96.8%
Current weight [pounds] 179.5 ± 45.9
Weight at age 18 129.1.5 ± 26.8
Height [inches] 64.7 ± 3.2
Body mass index [BMI] 30.1 ± 7.6
Symptoms < 7 months 0.6 %
7–12 months 1.5%
1–2 years 3.9%
2–4 years 13.1%
> 4 years 75.5%
Race/Ethnicity: Caucasian 91.5%
Afro-American 2.3%
American Indian 3.6%
Hispanic 2.6%
Asian 0.4%
Marital Status: Currently married 64.2%
Never married 11.2%
Divorced 17.4%
Widowed 2.5%
No children 26.5%
Number of Children: One child 16.5%
Two 30.5%
> 3 children 20.9%
Household income: < $9,000 4.9%
$10,000–$19,999 8.7%
$20,000–$29,999 8.8%
$30,000–$39,999 10.6%
$40,000–$49,999 10.4%
$50,000–$59,999 9.8%
$60,000–$69,999 7.5%
$70,000–$79,999 6.2%
$80,000–$89,999 5.2%
$90,000–$99,999 5.1%
$100,000–$199,999 9.7%
> $200,000 1.7%BMC Musculoskeletal Disorders 2007, 8:27 http://www.biomedcentral.com/1471-2474/8/27
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Symptoms and functionality
FM patients are usually poly-symptomatic with symptoms
and syndromes affecting several organ systems. Every
respondent in this survey reported multiple current symp-
toms and syndromes that have been associated with FM.
The most common symptom was low back pain followed
by recurrent headaches, arthritis, muscle-spasm, tingling,
and balance problems (Table 2). The average intensity of
symptoms over the past week was captured in response to
the question "please select the number that best describes
your experience with the following (specified problem) on
average during the past week". This questions was fol-
lowed by asking the respondents to evaluate each symp-
tom on a scale of 0 (no symptom) to 10 (extreme
symptom). The highest rated symptoms were: morning
stiffness, fatigue, poor sleep, and pain. A considerable
number of cognitive symptoms (i.e., problems with mem-
ory and concentration) were also acknowledged (Table 3).
Chronic pain, fatigue stiffness, and other FM-associated
symptoms frequently impact on an individual's func-
tional capabilities. Survey participants responded to the
question: "even if you did not do the following activities,
please indicate what you think your ability to do them
during the past week would be?" The percentage of
responders who indicated that they would have no diffi-
culty performing each task was as follows: normal activi-
ties of daily living (65%); walking 2 blocks (45%);
climbing stairs (38%); shopping (34%); light household
duties (e.g., cooking/dusting) (32%); lifting or carrying 10
pounds (30%); walking half a mile (27%); walking 1 mile
(18%); lifting or carrying 25 pounds (8%); heavy house-
hold duties (e.g., vacuuming/scrubbing) (7%); and stren-
uous recreational activity (hiking/biking) (3%).
The respondents were nearly equally divided regarding
their ability to maintain gainful employment. Those who
were still working felt that their symptoms compromised
their ability to be productive due to frequent absences and
reduced work hours. Approximately 20% of the respond-
ents had filed some form of disability claim and 6%
received workman's compensation.
Perceived aggravating factors
People with FM typically report that various events exacer-
bate their symptoms. These attributions were probed with
the question "which of the following factors act as triggers
that worsen your symptoms?" The respondents were per-
mitted to list as many as they wished and thus the percent-
ages do not sum to 100. The most common exacerbating
events acknowledged were mental stressors, weather
changes, sleeping problems and strenuous activity (Table
4).
Perceived triggering events
People with FM often associate a specific event to the
onset of their symptoms. In response to the question
"have any of the following potential triggering events
occurred around the same time that your fibromyalgia
symptoms first became apparent" Approximately 21% of
responders indicated that they could not identify any such
association. Over 73% of those who indicated some trig-
gering event made attributions to emotional trauma or
chronic stress (Table 5). The next most common attribu-
tion was acute illness (26.7%), followed by physical stres-
sors (surgery, motor vehicle collisions, and other
injuries). Another 20.6% of the responses acknowledged
physical or emotional abuse as a child and 15.1% associ-
ated abuse as an adult to the onset of their symptoms.
Childhood sexual abuse was cited by 9% of respondents.
Approximately 10.1% of the responders related the onset
of FM symptoms to the menopause.
Diagnosis and health care utilization
Most responders (98.4%) had been formally diagnosed as
having FM by a health care provider. In 55% of responders
the diagnosis had been made 4 or more years prior to the
completion of the survey, whereas in 9% the diagnosis
had been made within the last year. Rheumatologists were
responsible for the diagnosis in 42.4% of responders fol-
lowed by family physicians and internists in 23.2% and
12.2%, respectively. In just under 10% of responders the
diagnosis of FM was made by other health care providers
(chiropractors, nurse-practitioners, osteopaths, psychia-
trists, gynecologists, and nurses). Some 46% had con-
sulted between 3 to 6 health care providers before
obtaining the diagnosis of FM, while 24.6% had seen >6
health care providers prior to diagnosis. In response to the
question "how legitimate does your current health care
provider treat your fibromyalgia?", there was roughly a
bimodal distribution with 65.1% reporting "legitimate"
or "very legitimate", whereas 27.8% felt that their health
care provider did not view FM as a "very legitimate" disor-
der.
Over 96% of responders had seen a health care provider at
least once over the past year for their FM symptoms. Some
44% of responders reported that they had visited a health
care provider 1 to 4 times in the past year. An additional
23% indicated they visited responder 5 to 8 times in this
time period, 14% reported 9 to 12 visits, and 13%
reported more than 12 visits (13%). Approximately 29%
of respondents indicated they had visited an emergency
room on at least 1 to 4 occasions in the last year. Hospi-
talization due to FM symptoms was reported by 3.5% of
the responders.
Approximately 70.4% of the sample reported that they
had medical insurance. Most responders had out-of-BMC Musculoskeletal Disorders 2007, 8:27 http://www.biomedcentral.com/1471-2474/8/27
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pocket expenses related to management of their FM. For
instance 74% of responders reported spending between
$100 and $500 each month on over-the-counter prod-
ucts; whereas 61% spent between $100 and $500 each
month on prescription medications.
Management strategies
Survey participants were asked to "indicate whether you
use any of the following interventions for FM and if so,
whether each helps your FM symptoms". Respondents
rated the effectiveness of each intervention on a 0 to 10
scale, with 10 being most effective The interventions per-
ceived to be most effective (effectiveness rating ≥ 6.0) in
descending order were: rest, heat modalities, prescription
pain medications, prescription antidepressants, prescrip-
tion sleep medications, prayer, massage, and pool therapy
(Table 6).
Table 2: Frequencies of symptoms and current comorbidities ≥ 25 % [in descending order of frequency]
Current Symptom Frequency
Low back pain 63%
Recurrent headaches 47%
Arthritis 46%
Muscle spasm 46%
Tingling 46%
Balance problems 45%
Irritable bowel syndrome 44%
Numbness 44%
Chronic fatigue 40%
Bloating 40%
Depression 40%
Anxiety 38%
Sinus problems 37%
Tooth disorders 32%
Restless legs 32%
Tinnitus 30%
Jaw pain 29%
Bladder problems 26%
Rashes 25%
Table 3: Symptom intensity during the past week [in descending order of severity]
Symptom Mean ± SD
Morning stiffness 7.2 ± 2.5
Fatigue 7.1 ± 2.1
Nonrestorative sleep 6.8 ± 2.7
Pain 6.4 ± 2.0
Forgetfulness 5.9 ± 2.7
Concentration 5.9 ± 2.6
Difficulty falling asleep 5.6 ± 3.3
Muscle spasms 4.8 ± 3.2
Anxiety 4.5 ± 3.1
Depression 4.4 ± 3.1
Headaches 4.3 ± 3.1
Anger 3.9 ± 2.9
Restless legs 3.6 ± 2.7
Abdominal pain 3.6 ± 2.8
Poor balance 3.5 ± 2.9
Swelling of feet and ankles 3.2 ± 3.1
Dizziness 2.9 ± 2.8
Bladder problems 2.5 ± 2.9
Skin rashes 1.9 ± 2.9BMC Musculoskeletal Disorders 2007, 8:27 http://www.biomedcentral.com/1471-2474/8/27
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Medications used by survey responders
The Questionnaire listed 253 medications and asked
"which of the following medications do you currently use,
or have tried in the past to relieve symptoms due to fibro-
myalgia and were they helpful?" Respondents rated the
effectiveness of each intervention as "being helpful" (=
10) or "not helpful" (= 0). Table 7 presents the results in
4 columns: "every used ", " use now ", "continuing use "
(computed from (use now/every used) ×100), and "con-
sidered helpful ". The most commonly used medications
(ever used) were acetaminophen, nonsteroidals (NSAIDs),
tricyclic antidepressants, and cyclobenzaprine. The most
helpful medications (considered helpful) were: hydroco-
done preparations, aprazolam, oxycodone preparations,
zolpidem, clonazepam, cyclobenzaprine, and codeine
preparations. The medications used most consistently
used over time (continuing use) were: hydrocodone prepa-
rations, ibuprofen, clonazepam, acetaminophen, trazo-
done, gabapentin, and zolpidem.
Discussion
Over the course of 3 days, over 2500 respondents com-
pleted a survey that was posted on the web site of the
National Fibromyalgia Association. The demographics of
the respondents to this survey revealed no particular sur-
prises when compared to other epidemiologic studies and
surveys [1-12]. The household income was similar to a
previous survey of 537 FM patients in the San Diego, Cal-
Table 4: Factors perceived to worsen FM symptoms [in descending order of frequency]
Perceived stressor Frequency
Emotional distress 83%
Weather changes 80%
Sleeping problems 79%
Strenuous activity 70%
Mental stress 68%
Worrying 60%
Car travel 57%
Family conflicts 52%
Physical injuries 50%
Physical inactivity 50%
Infections 43%
Allergies 37%
Low to moderate physical activity 36%
Lack of emotional support 36%
Time zone changes 34%
Airplane travel 34%
Perfectionism 32%
Work related conflicts 29%
Menses 27%
Medication side effects 27%
Chemical exposures 27%
Sexual intercourse 17%
Table 5: Perceived triggering events of FM onset (in descending order of frequency)
Event Frequency
Chronic stress 41.9%
Emotional trauma 31.3%
Acute illness 26.7%
Physical injury (non-MVA) 17.1%
Surgery 16.1%
Motor vehicle accident (MVA) 16.1%
Emotional and physical abuse as an adult 12.2%
Emotional and physical abuse as a child 11.9%
Thyroid problems 10.3%
Menopause 10.1%
Sexual abuse as a child 8.7%
Childbirth 7.6%
Sexual abuse as adult 2.9%BMC Musculoskeletal Disorders 2007, 8:27 http://www.biomedcentral.com/1471-2474/8/27
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ifornia [20]. In comparison to United States National
Census figures, respondents were moderately overweight.
Several other studies have reported obesity in FM [21-23]
and weight reduction has been reported to provide
improvement [24]. This concordance in demographic var-
iables with other published FM studies suggests that the
Questionnaire provided a reasonably representative
measure.
It is difficult to make direct comparisons of health care uti-
lization in this survey and other studies, as it is largely
derived from patients with internet access in the United
States. For example, a Canadian study reported annual
visits to health care providers were 11.6, emergency room
visits were 0.6, and hospital inpatient days or 2.1 [25].
However, the health care system in Canada is a national-
ized service compared to the fee for service system in the
United States. It is impossible to disentangle the availabil-
ity and costs of services from service utilization.
Although a hallmark of FM is pain, the respondents listed
morning stiffness, fatigue, and non-restorative sleep
before pain, as comparable in severity. While morning
stiffness is a common symptom in inflammatory rheu-
matic disorders [26,27] it has only been mentioned in the
occasional FM study [28,29]. Morning stiffness is a char-
acteristic feature of inflammatory arthritidies, where it has
been defined as "slowness or difficulty moving the joints
when getting out of bed or after staying in one position
too long, which involves both sides of the body and gets
better with movement" [30]. Whether such a precise defi-
nition would apply to FM patients would be an interesting
topic for future study. Morning stiffness in rheumatoid
arthritis has been correlated with elevated serum levels of
hyaluronic acid [31]. Raised levels of hyaluronic acid have
been reported in one study FM patients [32], but not in
several others [33-35]. The 63% prevalence of low back
pain is particularly noteworthy, as this has not been previ-
ously reported in survey or epidemiological studies of FM.
It may be a productive topic for future research, as patients
Table 6: Interventions used by the survey responders [in descending order of frequency]
Intervention Frequency Effectiveness [0–10 scale]
Resting 86% 6.3 ± 2.5
Distraction [reading, watching TV etc.] 80% 4.7 ± 2.5
Heat modalities [warm water, hot packs] 74% 6.3 ± 2.3
Nutritional supplements 68% 3.8 ± 2.8
OTC pain medications 67% 3.8 ± 2.3
Prescription pain medications 66% 6.3 ± 2.4
Gentle walking 64% 4.6 ± 2.6
Prescription antidepressants 63% 6.2 ± 2.8
Stretching 62% 5.4 ± 2.6
Prayer 57% 6.0 ± 2.9
Prescription sleep medications 52% 6.5 ± 2.7
Relaxation/meditation 47% 5.1 ± 5.5
Massage/reflexology 43% 6.1 ± 2.8
Aerobic exercise 32% 5.0 ± 3.0
Cold therapy [ice packs etc.] 30% 4.8 ± 2.8
Chiropractic manipulation 30% 5.1 ± 3.0
Counseling [psychologist, MSW, pastor] 29% 4.8 ± 3.0
Pool therapy 26% 6.0 ± 3.0
Non-aerobic exercise [stretching, yoga, Tai 
Chi]
24% 5.1 ± 2.9
Physical therapy 24% 4.7 ± 3.1
OTC sleep medications 22% 4.0 ± 2.9
TENS unit 21% 4.3 ± 2.9
Trigger point injections 21% 5.0 ± 3.3
Support groups 19% 4.6 ± 3.0
Strength training 18% 4.3 ± 2.9
Pain clinic 17% 4.8 ± 3.1
Acupuncture 15% 4.5 ± 3.5
Pilates 8% 4.6 ± 3.3
Cognitive behavioral therapy 8% 4.3 ± 3.2
Energy healing [e.g. Reiki] 7% 4.0 ± 3.2
Biofeedback 6% 2.9 ± 2.9
Spinal surgery 4% 3.4 ± 3.4
Hypnosis 3% 2.5 ± 2.9BMC Musculoskeletal Disorders 2007, 8:27 http://www.biomedcentral.com/1471-2474/8/27
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with low back pain have been reported to develop FM in
25% of cases [36] and some patients with LBP have aug-
mented pain processing [37].
Six of the most frequently cited exacerbating factors
involved some form of emotional distress (endorsed by
83% of the respondents). These results are in accord with
several other studies [38-40]. The perceived adverse effect
of weather changes (80% endorsed) is noteworthy. This
effect has been previously reported [41] but in 2 studies
FM symptoms failed to correlate with meteorological var-
iables [42,43]. In another study pain was correlated with
high atmospheric pressure and low temperature [44].
Concordant with several other reports [45-47] "forgetful-
ness" and problems with "concentration" were rated as
quite common and problematical. The frequency of disa-
bility claims in the current survey was about the same as a
multicenter study in the United States [48].
One study of the prevalence of sexual abuse in FM sug-
gested that it might be as high as 57% [49]. The 7.8%
prevalence of childhood sexual abuse in the current sur-
vey is substantially lower and may reflect differences in
"candidness" between an Internet based survey popula-
tion and one-on-one interviews. A recent telephone based
study found no association between FM and sexual abuse,
but did report a three-fold increase of FM in women who
had been raped. Thus, it was hypothesized that chronic
stress, in the form of posttraumatic stress disorder, may
mediate the relationship between rape and FM [50].
Among the most interesting data to come out of this sur-
vey was the use of various management strategies and
medications by the participants. An attempt was also
made to assess the perceived effectiveness of various ther-
apies (on a 0 to 10 scale, with 10 being most effective).
The 3 most commonly used interventions were non-
medicinal (rest, heat, and distraction). Interventions with
the highest effectiveness ratings were: prescription sleep
medications (rating: 6.5), prescription pain medications
(rating: 6.3), resting (rating: 6.3), heat (rating: 6.3), and
prescription antidepressants (rating: 6.2). Although non-
prescription pain medications and nutritional supple-
ments were commonly used they did not appear to be par-
ticularly effective (ratings of 3.8 and 2.8 respectively).
Conversely, pool therapy, used by a quarter of the
respondents, was as effective as many of the more fre-
quently used management strategies.
Table 7: Medications used by ≥ 25% of the survey responders [% use sorted on "ever used"]
Drug (with common USA brand name) Ever used Use now Continuing use Considered helpful
Acetaminophen [Tylenol] 94 35 37 36
Ibuprofen [Motrin, Advil] 87 36 41 51
Naproxen [Naprosyn, Aleve] 66 13 20 39
Cyclobenzaprine [Flexeril] 64 19 30 58
Amitriptyline [Elavil] 55 12 22 42
Aspirin [Ecotrin] 53 10 19 34
Celecoxib [Celebrex] 48 6 13 40
Rofecoxib [Vioxx]* 48 0 0 39
Codeine + APAP [Tylenol #2 or #3 or #4] 47 4 9 55
Tramadol [Ultram] 46 13 28 44
Hydrocodone + APAP [Vicodin] 44 18 41 75
Propoxyphene + APAP [Darvocet] 44 8 18 54
Zolpidem [Ambien] 41 14 34 64
Sertraline [Zoloft] 41 8 20 40
Fluoxetine [Prozac] 39 8 21 42
Paroxetine [Paxil] 36 4 11 32
Buproprion [Wellbutrin] 35 10 29 41
Trazadone [Desyrel] 33 12 36 51
Gabapentin [Neurontin] 33 12 36 46
Aprazolam [Xanax] 33 10 30 70
Oxycodone + APAP [Percocet, Roxicet] 32 7 22 67
Venlafaxine [Effexor] 30 8 27 44
Melatonin [Melatonex] 28 5 18 35
Diazepam [Valium] 28 3 11 65
Tramadol + APAP [Ultracet] 27 7 26 49
Clonazepam [Klonopin] 25 10 40 61
Valdecoxib [Bextra]* 25 0 0 40
* No longer available in the USABMC Musculoskeletal Disorders 2007, 8:27 http://www.biomedcentral.com/1471-2474/8/27
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The most commonly used medications were acetami-
nophen (94%), ibuprofen (87%), naproxen (66%),
cyclobenzaprine (64%), and amitriptyline (55%). Based
on the percentage of respondents who rated medications
as helpful, the top 10 were: hydrocodone preparations
(75%), aprazolam (70%), oxycodone preparations
(67%), diazepam (65%), zolpidem (64%), clonazepam
(61%), cyclobenzaprine (58%), codeine preparations
(55%), propoxyphene preparations (54%), and ibupro-
fen (51%). Interestingly, there is a discrepancy between
the most commonly used and the most effective medica-
tions. This, discrepancy may be associated with the heavy
use of over-the-counter drugs, which are generally cheaper
than prescription drugs. There may also be a reluctance of
physicians to provide ongoing prescriptions of opioids
and benzodiazepines. The perceived effectiveness of
hydrocodone preparations is of some interest as this med-
ication has never been formally tested in FM patients.
Future research should examine the profile of health care
providers who prescribed this and similar opioids. Apra-
zolam (reported as being helpful in 70% of respondents)
has been noted to be of some benefit when used in con-
junction with ibuprofen [51], but has never been formally
evaluated as a stand-alone drug in FM.
Another way to consider effectiveness of medications is to
examine continuation of treatment. The most commonly
reported medications that respondents continuing to use
were: hydrocodone preparations (41%), ibuprofen
(41%), clonazepam (40%), acetaminophen (37%),
gabapentin (36%), trazodone (36%), zolpidem (34%),
aprozolam (30%), cyclobenzaprine (30%), and bupro-
pion (29%). As expected, newer medications available at
the end of 2005, such as duloxetine, sodium oxybate, and
pregabalin, were being used by only a small percentage of
respondents (i.e., < 8%). Non-adherence to prescribed
medications is reported to be common in FM patients
[52], but whether this is a result of lack of efficacy, side
effects, cost, or psychosocial factors, is not known.
In interpreting the results of this survey it is important to
acknowledge its limitations. The surveyed population was
self-selected as people with FM who had Internet access
and was familiar with the NFA website. Approximately
70% of the respondents indicated that they obtained
information about FM from the NFA (the sponsors of the
survey). It is possible that those familiar with NFA differ
in important ways from people with FM in general. They
were not personally interviewed or formally diagnosed.
Thus an unknown proportion of those responding may
not have met in 1990 ACR classification criteria for a diag-
nosis of FM [53]. However, only 1.6% of the responders
reported that their diagnosis of FM had not been con-
firmed by a health care professional. There is some evi-
dence that certain combinations of symptoms are strongly
correlated with an ACR based diagnosis of FM. For
instance, Katz has reported that a history of widespread
regional pain (score ≥ 8.0) plus fatigue (score ≥ 6.0) has a
75% concordance with ACR criteria [54]. This Internet
based survey was new and previously untested and there
is a need to confirm its psychometric properties in future
studies. Preliminary testing suggested good face validity
and test-retest reliability. Internet-based surveys are
increasingly used to obtain patient data [55] and several
studies have reported a good correlation with paper-and-
pencil surveys [56,57].
Conclusion
The information from this survey provides as a glimpse
into the FM landscape in the United States at the end of
2005 as perceived by a self-selected group of FM patients
with Internet access. These results pose several issues for
more in depth research, such as the prescribing habits of
FM health care providers, the role of emotional precipi-
tants, the impact of obesity, the significance of low back
pain and the nature of FM related stiffness.
Competing interests
The National Fibromyalgia Association received an unre-
stricted educational grant from Pfizer, Inc. for support of
this study. Pfizer Inc. had no role in implementing the
design of this study; in the collection, analysis, and inter-
pretation of data; in the writing of the manuscript; or in
the decision to submit the manuscript for publication.
Authors' contributions
RMB provided the statistical analysis and was responsible
for writing the manuscript with help and advice from the
co-authors.
JJ did the initial work in developing the questionnaire and
provided help with the methods
DCT participated in the statistical analysis and provided
help with the results and discussion
IJR participated in result analysis and the discussion
LM initiated this project, provided the website used in the
survey and provided editing advice
Acknowledgements
We thank the following members of the Task Force for their contributions 
to this manuscript:
• Richard Gevirtz, PhD, Alliant International University San Diego, CA
• Kim Jones, PhD, FNP, Oregon Health & Science University, Portland OR
• Philip Mease, MD, University of Washington, Seattle WA
• Shari McMahan, PhD, California State University, FullertonBMC Musculoskeletal Disorders 2007, 8:27 http://www.biomedcentral.com/1471-2474/8/27
Page 10 of 11
(page number not for citation purposes)
• Daniel Rooks, PhD, Harvard Medical School, Beth Israel-Deaconess Med-
ical Center, MA
• Dana Rutledge, RN, PhD, California State University, Fullerton
• Stuart Silverman, MD, University of California, Los Angeles, CA
Authors and members of the task force did not receive any funding, or any 
other remuneration, for their participation in this project.
References
1. White KP, Speechley M, Harth M, Ostbye T: The London Fibro-
myalgia Epidemiology Study: comparing the demographic
and clinical characteristics in 100 random community cases
of fibromyalgia versus controls.  J Rheumatol 1999, 26:1577-1585.
2. Lindell L, Bergman S, Petersson IF, Jacobsson LT, Herrstrom P: Prev-
alence of fibromyalgia and chronic widespread pain.  Scand J
Prim Health Care 2000, 18:149-153.
3. Jacobsson L, Lindgärde F, Manthorpe R: The commonest rheu-
matic complaints of over six weeks' duration in a twelve-
month period in a defined Swedish population. Prevalences
and relationships.  Scand J Rheumatol 1989, 18:353-360.
4. Forseth KO, Gran JT: The prevalence of fibromyalgia among
women aged 20–49 years in Arendal, Norway.  Scand J Rheuma-
tol 1992, 21:74-78.
5. Clark P, Burgos-Vargas R, Medina-Palma C, Lavielle P, Marina FF:
Prevalence of fibromyalgia in children: a clinical study of
Mexican children.  J Rheumatol 1998, 25:2009-2014.
6. Buskila D, Neumann L, Odes LR, Schleifer E, Depsames R, Abu-Shakra
M: The prevalence of musculoskeletal pain and fibromyalgia
in patients hospitalized on internal medicine wards.  Semin
Arthritis Rheum 2001, 30:411-417.
7. Bergman S, Herrstrom P, Hogstrom K, Petersson IF, Svensson B,
Jacobsson LT: Chronic musculoskeletal pain, prevalence rates,
and sociodemographic associations in a Swedish population
study.  J Rheumatol 2001, 28:1369-1377.
8. White KP, Speechley M, Harth M, Ostbye T: The London Fibro-
myalgia Epidemiology Study: the prevalence of fibromyalgia
syndrome in London, Ontario [In Process Citation].  J Rheu-
matol 1999, 26:1570-1576.
9. Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L: The prevalence
and characteristics of fibromyalgia in the general population.
Arthritis Rheum 1995, 38:19-28.
10. Salaffi F, De AR, Grassi W: Prevalence of musculoskeletal con-
ditions in an Italian population sample: results of a regional
community-based study. I. The MAPPING study.  Clin Exp
Rheumatol 2005, 23:819-828.
11. Cardiel MH, Rojas-Serrano J: Community based study to esti-
mate prevalence, burden of illness and help seeking behavior
in rheumatic diseases in Mexico City. A COPCORD study.
Clin Exp Rheumatol 2002, 20:617-624.
12. Topbas M, Cakirbay H, Gulec H, Akgol E, Ak I, Can G: The preva-
lence of fibromyalgia in women aged 20–64 in Turkey.  Scand
J Rheumatol 2005, 34:140-144.
13. Wolfe F, Pincus T: Standard self-report questionnaires in rou-
tine clinical and research practice – an opportunity for
patients and rheumatologists.  J Rheumatol 1991, 18:643-646.
14. Bennett R: The Fibromyalgia Impact Questionnaire (FIQ): a
review of its development, current version, operating char-
acteristics and uses.  Clin Exp Rheumatol 2005, 23:S154-S162.
15. Pincus T, Wolfe F: Patient questionnaires for clinical research
and improved standard patient care: is it better to have 80%
of the information in 100% of patients or 100% of the infor-
mation in 5% of patients?  J Rheumatol 2005, 32:575-577.
16. Pincus T: Why should rheumatologists collect patient self-
report questionnaires in routine rheumatologic care?  Rheum
Dis Clin North Am 1995, 21:271-319.
17. Boers M, Brooks P, Simon LS, Strand V, Tugwell P: OMERACT: an
international initiative to improve outcome measurement in
rheumatology.  Clin Exp Rheumatol 2005, 23:S10-S13.
18. National Fibromyalgia Association: NFA Internet Survey Ques-
tionnaire.   [http://fmawareorg0.web120.discountasp.net/survey/
2005/epidemological/emailBlast.htm]. (Electronic Citation 2005)
19. US Census Bureau: United States Census 2000.   [ h t t p : / /
www.census.gov/main/www/cen2000.html]. (Electronic Citation
2000)
20. Prince A, Bernard AL, Esdall AP: A descriptive analysis of fibro-
myalgia from the patient's perspective.  John of Musculoskeletal
Pain 2000, 8:35-47.
21. Patucchi E, Fatati G, Puxeddu A, Coaccioli S: Prevalence of fibro-
myalgia in diabetes mellitus and obesity.  Recenti Prog Med 2003,
94:163-165.
22. Yunus MB, Arslan S, Aldag JC: Relationship between body mass
index and fibromyalgia features.  Scand J Rheumatol 2002,
31:27-31.
23. Mengshoel AM, Haugen M: Health status in fibromyalgia – a fol-
lowup study.  J Rheumatol 2001, 28:2085-2089.
24. Shapiro JR, Anderson DA, noff-Burg S: A pilot study of the effects
of behavioral weight loss treatment on fibromyalgia symp-
toms.  J Psychosom Res 2005, 59:275-282.
25. White KP, Nielson WR, Harth M, Ostbye T, Speechley M: Does the
label "fibromyalgia" alter health status, function, and health
service utilization? A prospective, within-group comparison
in a community cohort of adults with chronic widespread
pain.  Arthritis Rheum 2002, 47:260-265.
26. Yazici Y, Pincus T, Kautiainen H, Sokka T: Morning stiffness in
patients with early rheumatoid arthritis is associated more
strongly with functional disability than with joint swelling
and erythrocyte sedimentation rate.  J Rheumatol 2004,
31:1723-1726.
27. Salvarani C, Cantini F, Boiardi L, Hunder GG: Polymyalgia rheu-
matica.  Best Pract Res Clin Rheumatol 2004, 18:705-722.
28. Grönblad M, Nyk:anen J, Konttinen Y, J:arvinen E, Helve T: Effect of
zopiclone on sleep quality, morning stiffness, widespread
tenderness and pain and general discomfort in primary fibro-
myalgia patients. A double-blind randomized trial.  Clin Rheu-
matol 1993, 12:186-191.
29. Russell IJ, Michalek JE, Kang YK, Richards AB: Reduction of morn-
ing stiffness and improvement in physical function in fibro-
myalgia syndrome patients treated sublingually with low
doses of human interferon-alpha.  J Interferon Cytokine Res 1999,
19:961-968.
30. Lineker S, Badley E, Charles C, Hart L, Streiner D: Defining morn-
ing stiffness in rheumatoid arthritis.  J Rheumatol 1999,
26:1052-1057.
31. Engstrom-Laurent A, Hallgren R: Circulating hyaluronic acid lev-
els vary with physical activity in healthy subjects and in rheu-
matoid arthritis patients. Relationship to synovitis mass and
morning stiffness.  Arthritis Rheum 1987, 30:1333-1338.
32. Yaron I, Buskila D, Shirazi I, Neumann L, Elkayam O, Paran D, Yaron
M: Elevated levels of hyaluronic acid in the sera of women
with fibromyalgia.  J Rheumatol 1997, 24:2221-2224.
33. Werle E, Jakel HP, Muller A, Fischer H, Fiehn W, Eich W: Serum
hyaluronic acid levels are elevated in arthritis patients, but
normal and not associated with clinical data in patients with
fibromyalgia syndrome.  Clin Lab 2005, 51:11-19.
34. Bliddal H, Moller HJ, Schaadt M, Danneskiold-Samsoe B: Patients
with fibromyalgia have normal serum levels of hyaluronic
acid.  J Rheumatol 2000, 27:2658-2659.
35. Barkhuizen A, Bennett RM: Elevated levels of hyaluronic acid in
the sera of women with fibromyalgia.  J Rheumatol 1999,
26:2063-2064.
36. Lapossy E, Maleitzke R, Hrycaj P, Mennet W, Muller W: The fre-
quency of transition of chronic low back pain to fibromyalgia.
Scand J Rheumatol 1995, 24:29-33.
37. Giesecke T, Gracely RH, Grant MA, Nachemson A, Petzke F, Wil-
liams DA, Clauw DJ: Evidence of augmented central pain
processing in idiopathic chronic low back pain.  Arthritis Rheum
2004, 50:613-623.
38. Kivimaki M, Leino-Arjas P, Virtanen M, Elovainio M, Keltikangas-
Jarvinen L, Puttonen S, Vartia M, Brunner E, Vahtera J: Work stress
and incidence of newly diagnosed fibromyalgia: prospective
cohort study.  J Psychosom Res 2004, 57:417-422.
39. Amir M, Kaplan Z, Neumann L, Sharabani R, Shani N, Buskila D: Post-
traumatic stress disorder, tenderness and fibromyalgia.  J Psy-
chosom Res 1997, 42:607-613.
40. Van Houdenhove B, Neerinckx E, Onghena P, Vingerhoets A, Lysens
R, Vertommen H: Daily hassles reported by chronic fatigue
syndrome and fibromyalgia patients in tertiary care: a con-Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Musculoskeletal Disorders 2007, 8:27 http://www.biomedcentral.com/1471-2474/8/27
Page 11 of 11
(page number not for citation purposes)
trolled quantitative and qualitative study.  Psychother Psychosom
2002, 71:207-213.
41. Hagglund KJ, Deuser WE, Buckelew SP, Hewett J, Kay DR:
Weather, beliefs about weather, and disease severity among
patients with fibromyalgia.  Arthritis Care Res 1994, 7:130-135.
42. de Blecourt AC, Knipping AA, de Voogd N, van Rijswijk MH:
Weather conditions and complaints in fibromyalgia.  J Rheu-
matol 1993, 20:1932-1934.
43. Fors EA, Sexton H: Weather and the pain in fibromyalgia: are
they related?  Ann Rheum Dis 2002, 61:247-250.
44. Strusberg I, Mendelberg RC, Serra HA, Strusberg AM: Influence of
weather conditions on rheumatic pain.  J Rheumatol 2002,
29:335-338.
45. Park DC, Glass JM, Minear M, Crofford LJ: Cognitive function in
fibromyalgia patients.  Arthritis Rheum 2001, 44:2125-2133.
46. Landro NI, Stiles TC, Sletvold H: Memory functioning in patients
with primary fibromyalgia and major depression and healthy
controls.  J Psychosom Res 1997, 42:297-306.
47. Grace GM, Nielson WR, Hopkins M, Berg MA: Concentration and
memory deficits in patients with fibromyalgia syndrome.  J
Clin Exp Neuropsychol 1999, 21:477-487.
48. Wolfe F, Anderson J, Harkness D, Bennett RM, Caro XJ, Goldenberg
DL, Russell IJ, Yunus MB: Work and disability status of persons
with fibromyalgia.  J Rheumatol 1997, 24:1171-1178.
49. Alexander RW, Bradley LA, Alarcon GS, Triana-Alexander M, Aaron
LA, Alberts KR, Martin MY, Stewart KE: Sexual and physical abuse
in women with fibromyalgia: association with outpatient
health care utilization and pain medication usage.  Arthritis
Care Res 1998, 11:102-115.
50. Ciccone DS, Elliott DK, Chandler HK, Nayak S, Raphael KG: Sexual
and physical abuse in women with fibromyalgia syndrome: a
test of the trauma hypothesis.  Clin J Pain 2005, 21:378-386.
51. Russell IJ, Fletcher EM, Michalek JE, McBroom PC, Hester GG:
Treatment of primary fibrositis/fibromyalgia syndrome with
ibuprofen and alprazolam: A double-blind, placebo-control-
led study.  Arthritis Rheum 1991, 34:552-560.
52. Sewitch MJ, Dobkin PL, Bernatsky S, Baron M, Starr M, Cohen M, et
al.: Medication non-adherence in women with fibromyalgia.
Rheumatology (Oxford) 2004, 43:648-54.
53. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Gold-
enberg DL, Tugwell P, Campbell SM, Abeles M, Clark P, Fam AG, Far-
ber SJ, Fiechtner JJ, Franklin CM, Gatter RA, Hamaty D, Lessard J,
Lichtbroun AS, Masi AT, McCain GA, Reynolds WJ, Romano TJ, Rus-
sell IJ, Sheon RP: The American College of Rheumatology 1990
criteria for the classification of fibromyalgia: Report of the
Multicenter Criteria Committee.  Arthritis Rheum 1990,
33:160-172.
54. Katz RS, Wolfe F, Michaud K: Fibromyalgia diagnosis: a compar-
ison of clinical, survey, and American College of Rheumatol-
ogy criteria.  Arthritis Rheum 2006, 54:169-176.
55. Eysenbach G, Wyatt J: Using the Internet for surveys and health
research.  J Med Internet Res 2002, 4:E13.
56. Kleinman L, Leidy NK, Crawley J, Bonomi A, Schoenfeld P: A com-
parative trial of paper-and-pencil versus computer adminis-
tration of the Quality of Life in Reflux and Dyspepsia
(QOLRAD) questionnaire.  Med Care 2001, 39:181-189.
57. Boeckner LS, Pullen CH, Walker SN, Abbott GW, Block T: Use and
reliability of the World Wide Web version of the Block
Health Habits and History Questionnaire with older rural
women.  J Nutr Educ Behav 2002, 34(Suppl 1):S20-S24.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2474/8/27/prepub